Commercialization Obligation Clause Samples

A Commercialization Obligation clause requires a party, typically a licensee, to actively pursue the development and marketing of a product or technology covered by an agreement. This clause may specify milestones, minimum sales targets, or timelines for bringing a product to market, and can include reporting requirements to demonstrate ongoing efforts. Its core function is to ensure that the licensed technology or product is not left unused, thereby protecting the licensor’s interests and maximizing the potential for commercial success.
Commercialization Obligation. Licensee shall undertake to use commercially reasonable efforts with regard to commercialization of the Products.
View SourceView Similar (6)
Commercialization Obligation. 15 CONFIDENTIAL TREATMENT REQUEST
View SourceView Similar (4)
Commercialization Obligation. Subsequent to development of the Module, SMI agrees to use reasonable efforts to (a) obtain necessary regulatory approvals for the marketing and sale of the Module in the International Territory, in those countries in which it elects to commercially distribute the Module, (b) provide for commercial production of the Module and (c) diligently market the Module after receipt of the necessary regulatory approvals, including, but not limited to, listing the Module in all of SMI's standard price lists and promoting and selling the Module at a level of effort and expense similar to the levels devoted to SMI's own patient monitoring equipment.
View SourceView Similar (2)
Commercialization Obligation. 24 4.5 Regulatory Process.............................................................................24 4.6
View SourceView Similar (2)
Commercialization Obligation. Alliant shall use commercially reasonable efforts to develop and commercialize the Licensed Products in North America, which efforts shall include: (a) commercial launch of Orapred ODT within sixty (60) days after Regulatory Approval by the FDA; and (b) allocation of efforts and resources consistent with the resources allocated by Alliant to the development and commercialization of Alliant’s other products with comparable commercial opportunity in the marketplace. Alliant shall be responsible for all costs and expenses incurred by Alliant in the development and commercialization of the Licensed Products in North America.
View SourceView Similar (2)
Commercialization Obligation. In order to maintain the license granted ---------------------------- hereunder in force, Licensee shall use reasonable efforts and due diligence (i) to pursue research and development for Products, and (ii) to obtain and maintain necessary governmental approvals for the sale of Products, as promptly as is reasonably and commercially feasible, and (iii) thereafter to produce and sell reasonable quantities of such Products in worldwide markets. Licensee shall keep Licensor and SKCC generally informed as to Licensee's progress for such research, development, approvals, production and sale, including its efforts, if any, to sublicense Licensor Patent Rights and/or Future Patent Rights. Licensee shall deliver to Licensor and SKCC an annual written report and such other reports as Licensor or SKCC may reasonably request. In the event Licensor, SKCC and Licensee cannot agree upon any matter related to Licensee's commercialization obligations, the parties agree to utilize arbitration pursuant to Article 9 hereof in order to resolve the matter. If the arbitrator determines that Licensee has not complied with its obligations hereunder as to a particular Product or Products, and such default is not fully cured within six (6) months after the arbitrator's decision, then Licensor may terminate this Agreement as to said particular Product or Products.
View Source
Commercialization Obligation. ▇▇▇▇ will exercise Commercially Reasonable Efforts to Market the Product to customers in the Territory during the Term at its sole cost and expense in accordance with the terms of this Agreement and Applicable Laws. Such efforts shall include the Launch of the Product, the preparation and delivery to CATALYST of: (i) an annual marketing plan for the Product (the first of which shall be delivered prior to the Launch Date); and (ii) sales projections for the Product on an annual basis. ▇▇▇▇ will provide CATALYST an opportunity to comment on such annual marketing plans, and will consider CATALYST’s comments in good faith, but the final marketing plan shall be determined by ▇▇▇▇ subject to complying with the other terms and conditions of this Agreement.
View Source

Related to Commercialization Obligation

  • Cooperation obligations The Parties undertake to cooperate to allow the timely submission, examination, publication and defence of any dissertation or thesis for a degree that includes their Results or Background subject to the confidentiality and publication provisions agreed in this Consortium Agreement.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection ▇▇▇▇▇; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.